10x Genomics, Inc. (TXG)
NASDAQ: TXG · Real-Time Price · USD
19.81
+0.67 (3.50%)
At close: Mar 24, 2026, 4:00 PM EDT
20.00
+0.19 (0.96%)
After-hours: Mar 24, 2026, 7:46 PM EDT
10x Genomics Stock Forecast
Stock Price Forecast
The 14 analysts that cover 10x Genomics stock have a consensus rating of "Hold" and an average price target of $17.18, which forecasts a -13.28% decrease in the stock price over the next year. The lowest target is $6.50 and the highest is $25.
Price Target: $17.18 (-13.28%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for 10x Genomics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 5 | 6 | 8 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 12 | 13 | 13 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $20 → $25 | Strong Buy | Maintains | $20 → $25 | +26.20% | Mar 2, 2026 |
| UBS | UBS | Hold Maintains $14 → $20 | Hold | Maintains | $14 → $20 | +0.96% | Feb 20, 2026 |
| Stifel | Stifel | Strong Buy Maintains $15 → $20 | Strong Buy | Maintains | $15 → $20 | +0.96% | Feb 13, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $18 → $19 | Hold | Maintains | $18 → $19 | -4.09% | Feb 13, 2026 |
| Leerink Partners | Leerink Partners | Hold Maintains $22 → $20 | Hold | Maintains | $22 → $20 | +0.96% | Jan 27, 2026 |
Financial Forecast
Revenue This Year
619.39M
from 642.82M
Decreased by -3.65%
Revenue Next Year
664.35M
from 619.39M
Increased by 7.26%
EPS This Year
-0.97
from -0.35
EPS Next Year
-0.76
from -0.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 655.2M | 721.4M | |||
| Avg | 619.4M | 664.4M | |||
| Low | 594.7M | 622.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.9% | 16.5% | |||
| Avg | -3.6% | 7.3% | |||
| Low | -7.5% | 0.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.72 | -0.23 | |||
| Avg | -0.97 | -0.76 | |||
| Low | -1.20 | -0.99 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.